CAS 143653-53-6
:Abciximab
Description:
Abciximab is a monoclonal antibody that functions as a glycoprotein IIb/IIIa inhibitor, primarily used in the medical field to prevent platelet aggregation during percutaneous coronary interventions. It is derived from murine sources and is chimeric in nature, combining both human and mouse components. Abciximab works by binding to the glycoprotein IIb/IIIa receptor on platelets, thereby blocking the binding of fibrinogen and other adhesive molecules, which is crucial for platelet aggregation and thrombus formation. This action helps reduce the risk of acute coronary events. The substance is administered intravenously and is often used in conjunction with other antiplatelet therapies. Its pharmacokinetics involve a rapid onset of action, with effects lasting for several hours post-administration. Common side effects may include bleeding complications, thrombocytopenia, and allergic reactions. Due to its specific mechanism of action, abciximab is particularly valuable in high-risk cardiac procedures, contributing to improved patient outcomes in the management of coronary artery disease.
Formula:Unspecified
Synonyms:- Immunoglobulin G1, anti-(human integrin αIIbβ3) Fab fragment (human-mouse monoclonal c7E3 clone p7E3VHhCγ1 γ1-chain), disulfide with human-mouse monoclonal c7E3 clone p7E3VκhCκ κ-chain
- Immunoglobulin G1, (human-mouse monoclonal c7E3 clone p7E3VHhCγ1 Fab fragment anti-human glycoprotein IIb/IIIa receptor), disulfide with human-mouse monoclonal c7E3 clone p7E3VκhCκ light chain
- Abciximab
- CentoRx
- C 7E3
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 2 products.
Abciximab
CAS:Abciximab: chimeric antibody, anti-platelet, blocks glycoprotein IIb/IIIa, vitronectin, Mac-1.Purity:SDS-PAGE:95.2%;SEC-HPLC:95.9%Color and Shape:LiquidMolecular weight:95.18 kDa
